Natasha Giordano Net Worth

The estimated Net Worth of Natasha Giordano is at least $913 Thousand dollars as of 15 March 2022. Ms Giordano owns over 4,100 units of PLx Pharma stock worth over $207 and over the last 8 years she sold PLXP stock worth over $0. In addition, she makes $912,328 as CEO and Pres & Director at PLx Pharma.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms Giordano PLXP stock SEC Form 4 insiders trading

Ms has made over 1 trades of the PLx Pharma stock since 2022, according to the Form 4 filled with the SEC. Most recently she bought 4,100 units of PLXP stock worth $14,965 on 15 March 2022.

The largest trade she's ever made was buying 4,100 units of PLx Pharma stock on 15 March 2022 worth over $14,965. On average, Ms trades about 315 units every 0 days since 2016. As of 15 March 2022 she still owns at least 5,186 units of PLx Pharma stock.

You can see the complete history of Ms Giordano stock trades at the bottom of the page.

Ms. Natasha Giordano biography

Natasha Giordano is the CEO, Pres & Director at PLx Pharma.

What is the salary of Ms Giordano?

As the CEO and Pres & Director of PLx Pharma, the total compensation of Ms Giordano at PLx Pharma is $912,328. There are no executives at PLx Pharma getting paid more.

How old is Ms Giordano?

Ms Giordano is 61, she's been the CEO and Pres & Director of PLx Pharma since . There are 8 older and 4 younger executives at PLx Pharma. The oldest executive at PLx Pharma Inc. is Patrick M. Lonergan, 86, who is the Member of Chief Exec. Officer Advisory Group.

What's Ms Giordano's mailing address?

Natasha's mailing address filed with the SEC is C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH SUITE 302, BEDMINSTER,, NJ, 07921.

Insiders trading at PLx Pharma

Over the last 8 years, insiders at PLx Pharma have traded over $0 worth of PLx Pharma stock and bought 841,160 units worth $2,548,334 . The most active insiders traders include West Asset Management Llc Park, Michael J Valentino, and David Emerson Jorden. On average, PLx Pharma executives and independent directors trade stock every 124 days with the average trade being worth of $2,403. The most recent stock trade was executed by Natasha Giordano on 15 March 2022, trading 4,100 units of PLXP stock currently worth $14,965.

What does PLx Pharma do?

PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with aspirin and ibuprofen, and potentially other drugs.

Complete history of Ms Giordano stock trades at Matinas Biopharma Inc and PLx Pharma

PLx Pharma executives and stock owners

PLx Pharma executives and other stock owners filed with the SEC include:

• Natasha Giordano,
  CEO, Pres & Director
• Robert Shawah,
  Chief Accounting Officer, Treasurer
• Rita M. O'Connor CPA, CPA,
  CFO and Head of Manufacturing & Supply Chain
• Michael J. Valentino,
  Exec. Chairman
• Michael Valentino,
  Director
• John Hadden,
  Director
• Natasha Giordano,
  Director
• Robert Casale,
  Director
• Kirk Calhoun,
  Director
• Anthony Bartsh,
  Director
• Gary Balkema,
  Director
• Tom Long,
  Vice President - Manufacturing & Technical Operations
• Steven Valentino,
  Vice President - Trade Sales
• Rita O Connor,
  Chief Financial Officer
• Harris Kaplan M.B.A., MBA,
  Member of Chief Exec. Officer Advisory Group
• Janet M. Barth,
  VP of Investor Relations & Corp. Communications
• Harris Kaplan MBA,
  Member of Chief Exec. Officer Advisory Group
• Charles Edmund Sheedy C.F.A., CFA,
  Member of Chief Exec. Officer Advisory Group
• Patrick M. Lonergan,
  Member of Chief Exec. Officer Advisory Group
• Nicole Godino,
  National Sales Director
• Joanne Cotignola,
  VP of Marketing
• Ronald R. Zimmerman,
  Founder & Sr. Advisor
• Efthymios Deliargyris,
  Chief Medical Officer
• West Asset Management Llc Park,
  10% owner
• David Emerson Jorden,
  Acting Chief Financial Officer
• Gary L Mossman,
  Chief Operating Officer
• David P Luci,
  Director